Trastuzumab (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Trastuzumab" in Spanish language version.

refsWebsite

Global rank Spanish rank

4^th place

2^nd place

low place

2,712^th place

2,374^th place

1,798^th place

agenciasinc.es

Romond, EH; Perez EA, Bryant J, et al. (2005). «Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer». New England Journal of Medicine 353 (16): 1673-1684. PMID 16236738. doi:10.1056/NEJMoa052122.
Piccart-Gebhart MJ, MJ; Procter M, Leyland-Jones B, et al. (2005). «Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer». New England Journal of Medicine 353 (16): 1659-1672. PMID 16236737. doi:10.1056/NEJMoa052306.
Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. (2006). «Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer». N Engl J Med 354 (8): 809-20. PMID 16495393. doi:10.1056/NEJMoa053028.
Javier Cortés; Sung-Bae Kim; Wei-Pang Chung; Seock-Ah Im, et al. (2022). «Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer». N Engl J Med 386: 1143-1154. doi:10.1056/NEJMoa2115022. Consultado el 25 de marzo de 2022.

Javier Cortés; Sung-Bae Kim; Wei-Pang Chung; Seock-Ah Im, et al. (2022). «Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer». N Engl J Med 386: 1143-1154. doi:10.1056/NEJMoa2115022. Consultado el 25 de marzo de 2022.

Romond, EH; Perez EA, Bryant J, et al. (2005). «Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer». New England Journal of Medicine 353 (16): 1673-1684. PMID 16236738. doi:10.1056/NEJMoa052122.
Piccart-Gebhart MJ, MJ; Procter M, Leyland-Jones B, et al. (2005). «Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer». New England Journal of Medicine 353 (16): 1659-1672. PMID 16236737. doi:10.1056/NEJMoa052306.
Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. (2006). «Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer». N Engl J Med 354 (8): 809-20. PMID 16495393. doi:10.1056/NEJMoa053028.
Metcalfe, S; Evans J; Priest G. (2007). «PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer». N Z Med J 120 (1256): 1U2593. PMID 17589560.